Skip to main content

Advertisement

Table 1 Parameter values

From: A mathematical model with time-varying delays in the combined treatment of chronic myeloid leukemia

Param Physical interpretation Estimated value (units) Reference
τ delay for development of CTL cells 7 [days] [9]
θ maximal period to react to imatinib 20 [days] [6]
μ x death rate of cancer cells 0.2 [0, 0.8] [days−1] [23]
μ y death rate of effector T cells 0.06 [0, 0.5] [days−1] [24]
η 1 saturation effect of CML cells in the lymph nodes 100 [cells][ml−1] [9]
η 2 saturation effect of immune cell recruitment by cancer cells 2 × 107 [cells][ml−1] [24]
β 1 growth rate of CML cancer cells in the form of the Gompertz law 0.03 [0; 0.5] [days−1] [9]
β 2 change in the effector T cell (y(t)) population due to encounters with CML antigen 0.41 × 0.001 [days−1] [25], [26]
γ 1 loss of CML cancer cells due to encounters with the effector T cells 0.005 [days 1 [ cells ml ] 1 ] [9]
γ 2 loss of CTL cells due to these encounters between CTL and CML cancer cells 0.005 [days 1 [ cells ml ] 1 ] [26]
γ 3 factor using imatinib treatment 0.00014 [mg]−1 Estimated
γ 4 factor using IFN-a treatment 0.005 [mg]−1 Estimated
ω once-daily dose of imatinib 400 - 800 [mg/day] [1]
i n α IFN-a dose 13 [mg/days] (90 [mg] weekly) [27]
K constant, the maximum possible concentration of CML [1.5 × 105;4 × 105] [cells/ml] [9]